Navigation Links
Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
Date:1/28/2009

Product is Japan's first second-generation drug-eluting stent

NATICK, Mass., Jan. 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System. The Company plans to launch the product as soon as reimbursement approval is granted, which is expected in the coming weeks.

TAXUS Liberte is the only second-generation drug-eluting stent approved for use in Japan. Design improvements over the Company's first-generation TAXUS(R) Express2(TM) Stent include thinner struts to allow better stent deliverability and conformability, as well as a more uniform stent geometry for consistent lesion coverage and drug distribution.

"The TAXUS Liberte Stent is the latest advance in drug-eluting stent technology for Japan," said Donald Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "Its safety and efficacy have been well demonstrated in multiple clinical studies and years of clinical use."

"We are very pleased with this approval, which provides access to proven technology to Japanese physicians and their patients," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We are committed to continuing to provide the most innovative products and therapies to the Japanese market."

The TAXUS Liberte Stent uses proven paclitaxel-eluting technology, which has been evaluated by the industry's most extensive randomized, controlled clinical trial program, and studied in 35,000 real-world patients enrolled in post-approval registries. More than 4.6 million TAXUS Stent Systems have been implanted globally.

The TAXUS Liberte Stent will replace the TAXUS Express2
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
2. Boston Scientific Acquires Labcoat Limited
3. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
4. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
5. Boston Scientific to Participate in Piper Jaffray Health Care Conference
6. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
7. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
8. FDA Approves Boston Scientifics Apex(TM) PTCA Dilatation Catheter
9. InterMune to Present at Deutsche Bank Biotech Boston Confab
10. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
11. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 The Board of Directors of BD (Becton, ... a quarterly dividend of 54.5 cents per common share payable ... 9, 2014. The indicated annual dividend rate is $2.18 per ... a leading medical technology company that partners with customers and ... evolving health needs. Our innovative solutions are focused on improving ...
(Date:7/22/2014)...   BioTE Medical , a leading provider ... pellets, today announced the addition of Dr. ... Rouzier is joining the BioTE Medical Advisory Board ... Rouzier was residency trained in Family Medicine and ... certified emergency physician still practicing at a large ...
(Date:7/22/2014)... Chicago, IL (PRWEB) July 22, 2014 ... will a clear and concise visual representation of history, ... Mr. Novak was always regaled by family history stories ... historic location as the "old country." Pictures and 8mm ... and undiscovered side of the family, and Steve ordered ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 /PRNewswire/ ... filiale di BGI, la maggiore organizzazione di genomica del ... servizio di sequenziamento dell,intero esoma umano con base la ... Complete Genomics, molto apprezzata nel settore per essere ... il 99.999% di precisione e una rilevazione altamente sensibile ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2
... Mich., Sept. 10 The primary objective of ... the delivery of,biomedical advances to the marketplace. ... at Boston University on,Friday, September 7th with noted ... Presidents of both Boston,University and Fraunhofer Gesellschaft. ...
... by prominent,Board members Robert Windom, M.D. and Steven ... with inventor Dr. Budimir Drakulic -,have this day ... approved, ambulatory 12-lead ECG cardiovascular,monitor. In private ... ten,days, the trio of cardiovascular experts and Signalife,s ...
... (Amex: PTN ) today announced it has ... melanocortin agonist drug,candidate for the treatment of male ... King Pharmaceuticals Inc. (NYSE: KG ). ... development,and marketing agreement on bremelanotide, with King exercising ...
Cached Biology Technology:'Alliance for Medical Devices, Instrumentation and Diagnostics' formed between Fraunhofer Center for Manufacturing Innovation and Boston University 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 2Signalife's Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor 3Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 2Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program 3
(Date:7/22/2014)... In contrast to their negative reputation as disease ... and evolutionary functions that help to shape the ... new report by the American Academy of Microbiology. ... influence all life forms on the planet, from ... and driving major speciation events," states Marilyn Roossinck ...
(Date:7/22/2014)... NY -- Stem cells offer much promise for treating ... stem cell survival is poor, limiting their effectiveness. New ... survival and optimize their therapeutic function after transplantation, as ... Access , a peer-reviewed journal from Mary Ann Liebert, ... BioResearch Open Access website . ...
(Date:7/22/2014)... hear that drinking milk helps make their bones strong or that ... the idea that if something is good for us, it must ... Journal of Consumer Research , when children hear about the benefits ... predicted that when food is presented to children as making them ... learning how to read or count, they would conclude the food ...
Breaking Biology News(10 mins):Report on viruses looks beyond disease 2
... academic, government and industry researchers has completed a first draft ... important first step in accelerating the pace of research on ... that face cassava farmers around the world. Cassava is ... for more than 750 million people each day. Although it ...
... 9 Genencor, a division of Danisco, has ... American Institute of Chemical Engineers (AIChE) for its ... Robert Davis, Chair of the AIChE Awards committee, ... Marketing Director, Biomass Enzymes and Accellerase® Product Manager, ...
... A chemical culprit responsible for the rapid, mysterious death ... found by collaborating scientists at Rutgers University and the ... may hold unexpected promise in cancer research. The ... in a virus that has been attacking and killing ...
Cached Biology News:Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... A cleaning agent for removing ... countertops, and pipettors. It ... RNase contamination from microcentrifuge tubes ... ,RNase Zap (R) ...
Mol wt: average mol wt12,360.96 Da by calculation...
... a series of media originally developed at the ... for the large scale propagation of cells from ... used for the growth and maintenance of cell ... viruses in these cell lines. One of the ...
Biology Products: